ADHD In Japan Starting To Find An Easier Regulatory Path; Shire Advances Pipeline
This article was originally published in PharmAsia News
Executive Summary
Shire recently initiated a Phase II/III study for Intuniv, and Vyvanse is not far behind. Currently only two products are approved for ADHD in Japan.